Literature DB >> 18572275

Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology.

Winnie S Liang1, Travis Dunckley, Thomas G Beach, Andrew Grover, Diego Mastroeni, Keri Ramsey, Richard J Caselli, Walter A Kukull, Daniel McKeel, John C Morris, Christine M Hulette, Donald Schmechel, Eric M Reiman, Joseph Rogers, Dietrich A Stephan.   

Abstract

While the clinical and neuropathological characterization of Alzheimer's Disease (AD) is well defined, our understanding of the progression of pathologic mechanisms in AD remains unclear. Post-mortem brains from individuals who did not fulfill clinical criteria for AD may still demonstrate measurable levels of AD pathologies to suggest that they may have presented with clinical symptoms had they lived longer or are able to stave off disease progression. Comparison between such individuals and those clinically diagnosed and pathologically confirmed to have AD will be key in delineating AD pathogenesis and neuroprotection. In this study, we expression profiled laser capture microdissected non-tangle bearing neurons in 6 post-mortem brain regions that are differentially affected in the AD brain from 10 non-demented individuals demonstrating intermediate AD neuropathologies (NDAD; Braak stage of II through IV and CERAD rating of moderate to frequent) and evaluated this data against that from individuals who have been diagnosed with late onset AD as well as healthy elderly controls. We identified common statistically significant expression changes in both NDAD and AD brains that may establish a degenerative link between the two cohorts, in addition to NDAD specific transcriptomic changes. These findings pinpoint novel targets for developing earlier diagnostics and preventative therapies for AD prior to diagnosis of probable AD. We also provide this high-quality, low post-mortem interval (PMI), cell-specific, and region-specific NDAD/AD reference data set to the community as a public resource. Copyright (c) 2008 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18572275      PMCID: PMC2844804          DOI: 10.1016/j.neurobiolaging.2008.05.013

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  83 in total

1.  Synaptogyrins regulate Ca2+-dependent exocytosis in PC12 cells.

Authors:  S Sugita; R Janz; T C Südhof
Journal:  J Biol Chem       Date:  1999-07-02       Impact factor: 5.157

2.  Two sites of action for synapsin domain E in regulating neurotransmitter release.

Authors:  S Hilfiker; F E Schweizer; H T Kao; A J Czernik; P Greengard; G J Augustine
Journal:  Nat Neurosci       Date:  1998-05       Impact factor: 24.884

3.  MRI of entorhinal cortex in mild Alzheimer's disease.

Authors:  M Bobinski; M J de Leon; A Convit; S De Santi; J Wegiel; C Y Tarshish; L A Saint Louis; H M Wisniewski
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

Review 4.  Mechanisms of vertebrate synaptogenesis.

Authors:  Clarissa L Waites; Ann Marie Craig; Craig C Garner
Journal:  Annu Rev Neurosci       Date:  2005       Impact factor: 12.449

5.  Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype.

Authors:  Y Davidson; L Gibbons; A Pritchard; J Hardicre; J Wren; J Tian; J Shi; C Stopford; C Julien; J Thompson; A Payton; U Thaker; A J Hayes; T Iwatsubo; S M Pickering-Brown; N Pendleton; M A Horan; A Burns; N Purandare; C L Lendon; D Neary; J S Snowden; D M A Mann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04       Impact factor: 10.154

Review 6.  Normal and pathological aging--findings of positron-emission-tomography.

Authors:  R Mielke; J Kessler; B Szelies; K Herholz; K Wienhard; W D Heiss
Journal:  J Neural Transm (Vienna)       Date:  1998       Impact factor: 3.575

7.  Multiple protein domains contribute to the action of the copper chaperone for superoxide dismutase.

Authors:  P J Schmidt; T D Rae; R A Pufahl; T Hamma; J Strain; T V O'Halloran; V C Culotta
Journal:  J Biol Chem       Date:  1999-08-20       Impact factor: 5.157

8.  The copper chaperone CCS is abundant in neurons and astrocytes in human and rodent brain.

Authors:  J D Rothstein; M Dykes-Hoberg; L B Corson; M Becker; D W Cleveland; D L Price; V C Culotta; P C Wong
Journal:  J Neurochem       Date:  1999-01       Impact factor: 5.372

9.  Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer's disease.

Authors:  G B Frisoni; M P Laakso; A Beltramello; C Geroldi; A Bianchetti; H Soininen; M Trabucchi
Journal:  Neurology       Date:  1999-01-01       Impact factor: 9.910

10.  Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.

Authors:  Stephen D Ginsberg; Shaoli Che; Scott E Counts; Elliott J Mufson
Journal:  J Neurochem       Date:  2006-03       Impact factor: 5.372

View more
  35 in total

Review 1.  Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective.

Authors:  Puneet Talwar; Juhi Sinha; Sandeep Grover; Chitra Rawat; Suman Kushwaha; Rachna Agarwal; Vibha Taneja; Ritushree Kukreti
Journal:  Mol Neurobiol       Date:  2015-09-09       Impact factor: 5.590

Review 2.  Single-cell and regional gene expression analysis in Alzheimer's disease.

Authors:  Ruby Kwong; Michelle K Lupton; Michal Janitz
Journal:  Cell Mol Neurobiol       Date:  2012-01-22       Impact factor: 5.046

Review 3.  Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease.

Authors:  Greg M Cole; Sally A Frautschy
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

4.  The workflow from post-mortem human brain sampling to cell microdissection: a Brain Net Europe study.

Authors:  David Meyronet; Aline Dorey; Patrick Massoma; Catherine Rey; Eudeline Alix; Karen Silva; Corinne Perrin; Isabelle Quadrio; Armand Perret-Liaudet; Nathalie Streichenberger; Nicole Thomasset; Jérôme Honnorat; Thomas Arzberger; Hans Kretzschmar
Journal:  J Neural Transm (Vienna)       Date:  2015-05-16       Impact factor: 3.575

Review 5.  A systems approach to drug discovery in Alzheimer's disease.

Authors:  Michael Shelanski; William Shin; Soline Aubry; Peter Sims; Mariano J Alvarez; Andrea Califano
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

6.  Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus.

Authors:  Ben Readhead; Jean-Vianney Haure-Mirande; Cory C Funk; Matthew A Richards; Paul Shannon; Vahram Haroutunian; Mary Sano; Winnie S Liang; Noam D Beckmann; Nathan D Price; Eric M Reiman; Eric E Schadt; Michelle E Ehrlich; Sam Gandy; Joel T Dudley
Journal:  Neuron       Date:  2018-06-21       Impact factor: 17.173

7.  Synaptic gene dysregulation within hippocampal CA1 pyramidal neurons in mild cognitive impairment.

Authors:  Scott E Counts; Melissa J Alldred; Shaoli Che; Stephen D Ginsberg; Elliott J Mufson
Journal:  Neuropharmacology       Date:  2013-10-25       Impact factor: 5.250

8.  Alzheimer's disease is associated with altered expression of genes involved in immune response and mitochondrial processes in astrocytes.

Authors:  Shobana Sekar; Jacquelyn McDonald; Lori Cuyugan; Jessica Aldrich; Ahmet Kurdoglu; Jonathan Adkins; Geidy Serrano; Thomas G Beach; David W Craig; Jonathan Valla; Eric M Reiman; Winnie S Liang
Journal:  Neurobiol Aging       Date:  2014-10-02       Impact factor: 4.673

Review 9.  Why pleiotropic interventions are needed for Alzheimer's disease.

Authors:  Sally A Frautschy; Greg M Cole
Journal:  Mol Neurobiol       Date:  2010-05-02       Impact factor: 5.590

Review 10.  Non-Demented Individuals with Alzheimer's Disease Neuropathology: Resistance to Cognitive Decline May Reveal New Treatment Strategies.

Authors:  Olga Zolochevska; Giulio Taglialatela
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.